Hydroxychloroquine-induced hyperpigmentation in a 14-year-old female with systemic lupus erythematosus

Article Page


Hydroxychloroquine (HCQ)-induced hyperpigmentation is uncommon but is increasingly recognized. To our knowledge, HCQ-induced hyperpigmentation has not been reported in the pediatric age group. Herein, we present the case of a 14-year-old girl with systemic lupus erythematosus, who developed hyperpigmentation on her shins and dorsum of the left foot, approximately 3 years after initiating treatment with HCQ. Physicians who treat children with HCQ for reasons such as rheumatologic disorders, dermatologic disorders and, more recently, coronavirus disease-19 should be aware of this less-known side effect of HCQ.

Keywords: chloroquine, COVID-19, dermatologic disorders, melanin, rheumatologic disorders.

Citation: Leung AKC, McMillan T, Human A, Lam JM. Hydroxychloroquineinduced hyperpigmentation in a 14-year-old female with systemic lupus erythematosus. Drugs in Context 2020; 9: 2020-5-8. DOI: 10.7573/dic.2020-5-8

Contributions: Professor Alexander KC Leung wrote the first draft of the article and oversaw the manuscript creation. Dr McMillan, Dr Human and Dr Lam were involved with the care of this patient and helped with the draft and revision of this manuscript. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: Professor Alexander KC Leung is an associate editor of Drugs in Context and confirms that this article has no conflicts of interest otherwise. This manuscript was sent out for independent peer review by the Editor-in-Chief. All other authors declare that they have no conflicts of interest relevant to this manuscript. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2020/07/dic.2020-5-8-COI.pdf

Acknowledgements: None.

Funding declaration: Professor Leung, Dr McMillan, Dr Human, and Dr Lam disclose no relevant financial relationship. There was no funding associated with the preparation of this article.

Copyright: Copyright © 2020 Leung AKC, McMillan T, Human A, Lam JM. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2020 Leung AKC, McMillan T, Human A, Lam JM. https://doi.org/10.7573/dic.2020-5-8. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/hydroxychloroquine-induced-hyperpigmentation-in-a-14-year-old-female-with-systemic-lupus-erythematosus

Correspondence: Alexander KC Leung, The University of Calgary, Alberta Children’s Hospital, #200, 233 – 16th Avenue NW, Calgary, Alberta, Canada T2M 0H5. aleung@ucalgary.ca

Provenance: Invited; externally peer reviewed.

Submitted: 20 May 2020; Peer review comments to author: 12 June 2020; Revised manuscript received: 17 June 2020; Accepted: 24 June 2020; Publication date: 20 July 2020.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editorial office editorial@drugsincontext.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF